



KMCH INSTITUTE OF HEALTH SCIENCES AND RESEARCH

(A unit of Kovai Medical Center and Hospital Limited)

Coimbatore, Tamil Nadu

Department of Pharmacology


New Drug Update

(New Drugs and Available Drugs with New Formulation)

New drugs approved by FDA

1. Idecabtagene vicleucel
2. Dasiglucagon
3. Ponesimod
4. Oritavancin
5. Tivozanib
6. Dexmethylphenidate and Serdexmethylphenidate

**Nothing Worth Having
Comes Easy**



**Series - 21
April 2021**

| | |
|---|---|
| <p style="text-align: center;">1. Idecabtagene vicleucel</p> | <p style="text-align: center;">2. Dasiglucagon</p> |
| <p>Date of Approval: March 26, 2021 Mechanism of action: B-cell maturation antigen (BCMA)-directed genetically modified autologous chimeric antigen receptor (CAR) T cell immunotherapy Indication: Relapsed or refractory multiple myeloma Dosage Formulation: Intravenous Infusion</p> | <p>Date of Approval: March 22, 2021 Mechanism of action: Glucagon analogue Indication: Severe hypoglycemia in diabetes patients aged 6 years and older Dosage Formulation: Prefilled autoinjector for subcutaneous injection</p> |
| <p style="text-align: center;">3. Ponesimod</p> | <p style="text-align: center;">4. Oritavancin</p> |
| <p>Date of Approval: March 18, 2021 Mechanism of action: Selective sphingosine-1-phosphate receptor 1 (S1P1) modulator Indication: Relapsing Multiple Sclerosis Dosage Formulation: Tablet</p> | <p>Date of Approval: March 12, 2021 Mechanism of action: Lipoglycopeptide antibiotic acts by inhibiting cell wall synthesis Indication: Acute bacterial skin and skin structure Infection Dosage Formulation: Intravenous Infusion</p> |
| <p style="text-align: center;">5. Tivozanib</p> | <p style="text-align: center;">6. Dexmethylphenidate and Serdexmethylphenidate</p> |
| <p>Date of Approval: March 10, 2021 Mechanism of action: Suppresses angiogenesis by inhibiting Vascular endothelial growth factor receptor (Tyrosine kinase inhibitor) Indication: Refractory advanced renal cell carcinoma Dosage Formulation: Capsule</p> | <p>Date of Approval: March 2, 2021 Mechanism of action: Prodrug of Methylphenidate acts by blocking the reuptake of norepinephrine and dopamine Indication: Attention Deficit Hyperactivity Disorder Dosage Formulation: Capsule</p> |